One-shot chikungunya vaccine found safe, effective in first phase 3 trial ...Middle East

Business Standard - Economy
One-shot chikungunya vaccine found safe, effective in first phase 3 trial
A single-dose vaccine for chikungunya was found safe and produced a strong immune response against the viral disease, according to the first phase 3 trial of the preventive published in The Lancet journal. However, the researchers were unable to investigate whether the VLA1553 vaccine, developed by French biotech company Valneva, protects against subsequent disease since the study was not conducted in regions where chikungunya is endemic. Chikungunya is a mosquito-borne disease caused by the chikungunya virus (CHIKV), which is endemic in some regions of Africa, Asia, and the Americas. It causes a fever in patients roughly four to eight days after they have been bitten by an infected mosquito

Hence then, the article about one shot chikungunya vaccine found safe effective in first phase 3 trial was published today ( ) and is available on Business Standard ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( One-shot chikungunya vaccine found safe, effective in first phase 3 trial )

Apple Storegoogle play

Last updated :

Also on site :